UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☐ Definitive Additional Materials

☒ Soliciting Material Under §240.14a-12

NABI BIOPHARMACEUTICALS

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ Fee paid previously with preliminary materials.

☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Biota Pharmaceuticals

Biota and Nabi Merger Overview

April 2012

biota

NABI BIOPHARMACEUTICALS

Forward Looking Statement

Forward Looking Statement Regarding Biota

This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Biota and Nabi can give no assurance that these expectations will prove to be correct.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.

We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Relenza ® is a registered trademark of GlaxoSmithKline.

Inavir ® is a registered trademark of Daiichi Sankyo.

Forward Looking Statements regarding the Proposed Nabi-Biota Transaction

This presentation also contains forward-looking statements about the occurrence, timing and financial terms or effect of the proposed merger between Nabi and Biota, including expected timing for closing, which are based on certain assumptions made by us based on current conditions, expected future developments and other factors we believe are appropriate in the circumstances. No assurances can be given, however, that these activities, events or developments will occur or that such results will be achieved. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Nabi or Biota. Several of these risks associated with Nabi are outlined in Nabi's most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other documents Nabi files with the Securities and Exchange Commission ("SEC"). We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Additional Information

In connection with the proposed merger and related matters involving Nabi and Biota, Nabi will file with the SEC a proxy statement and will mail or otherwise disseminate the proxy statement and a form of proxy to its shareholders when it becomes available. SHAREHOLDERS AND INVESTORS ARE ENCOURAGED TO READ THE PROXY STATEMENT (AND OTHER RELEVANT MATERIALS) REGARDING THE PROPOSED TRANSACTIONS CAREFULLY AND IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE, AND BEFORE MAKING ANY VOTING DECISION, AS IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTIONS.

Shareholders and investors will be able to obtain a free copy of the proxy statement (when available), as well as other filings made by Nabi regarding Nabi Biopharmaceuticals, Biota Holdings Limited and the proposed transactions, without charge, at the SEC website at www.sec.gov . In addition, documents filed with the SEC by Nabi will be available free of charge on the investor relations portion of the Nabi website at www.nabi.com.

Certain Information Regarding Participants

Nabi and certain of its directors and executive officers, may be deemed, under SEC rules, to be participants in the solicitation of proxies from its shareholders in connection with the proposed transactions described above. The names of Nabi's directors and executive officers and a description of their interests in Nabi are set forth in Nabi's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, which was filed with the SEC on March 14, 2012, and Nabi's Proxy Statement dated April 20, 2011 which was filed with the SEC on the same date. Additional information about the interests of potential participants will be contained in the proxy statement (when filed) and other relevant materials to be filed with the SEC in connection with the proposed transactions. These documents may be obtained from the SEC website and from Nabi in the manner noted above.

Merger Rationale

- Opportunity for Biota to achieve a transformational platform for growth
- Enables Nabi to transition into a revenue generating, late stage integrated biotechnology company
- Result is a leading company in anti-infective drug discovery and development

Merger Rationale

The Combined Company Will Possess Multiple Attractive Qualities

	Biota Pharmaceuticals
Three royalty generating products	✓
$231M BARDA contract	✓
Balance of clinical and preclinical products	✓
$100M+ of cash	✓
Ability to fund clinical programs	✓
Ability to manage Relenza royalty patent cliff	✓

Key Aspects of the Merger

- Nabi will acquire all of the outstanding ordinary shares in Biota
- Nabi's post-merger assets will include US$54 million in cash, a right to receive royalties from a marketed product (PhosLyra) and an interest in NicVAX vaccine
- Nabi plans to return to its stockholders its remaining cash in excess of the US$54 million required to be held by Nabi at closing after satisfying outstanding liabilities
- Nabi's intends to distribute contingent value right related to NicVAX
- Immediately following the closing of the merger, the board of directors of the combined company will consist of six current Biota Directors and two current Nabi Directors. Also, Biota's current CEO and CFO will serve as the CEO and CFO, respectively, of the combined company and additional US-based executives will be appointed

Pro Forma Nabi / Biota

- Combined Pipeline:

Product	Preclinical	Phase 1	Phase 2	Phase 3	NDA	Market	Partner
Relenza	Influenza Treatment and Prevention						GSK (WW)
Inavir	Influenza Treatment (JAP)						Daiichi Sankyo (JAP)
PhosLo	End Stage Renal Disease						Fresenius Medical Care (WW)
BTA-798	HRV						
LANI	Influenza (ROW)						BARDA
NicVax	Smoking Cessation and Relapse Prevention (EU)						
RSV Program	RSV						NIH
FLUNET	Influenza						
Other	Gyrase, HCV-NN, CDI						NIH (CDI only)

Potential Upcoming Key Events

Biota Pharmaceuticals – Potential For A Series of Value-Creating Events



Experienced and Proven Management Team and Board

Peter Cook M.Pharm
CEO & Managing Director

Damian Lismore
CFO & Company Secretary

Jane Ryan
VP, Product Development & Strategic Management

Leigh Farrell
VP, Business Development

Simon Tucker, PhD
VP, Research

John Lambert, PhD
VP, Product Development Operations

Anticipated Merger Timeline

Merger Agreement announced	23 April
Scheme Booklet/Proxy to Shareholders	June
Meetings of Shareholders	Aug/Sept
Biota Pharmaceuticals Inc. listed on Nasdaq	September

Biota Portfolio

Influenza Seasonal Market

- Seasonal or prescription market ~US$1.0bn annually
  - Occurs annually during autumn and winter in temperate regions
  - Circulates between hemispheres with two peaks in tropical countries
  - Approximately 3-5 million cases of severe illness worldwide
    - Approx 250,000 to 500,000 deaths mostly in the very young and over 65s
  - Distribution channel – prescription and pharmacy



Sources: WHO Website – Influenza; Sales data 2002/03-2009/10: IMS Health as of 30 Jun 2010; Sales data 2010/11: Roche, GSK & Daiichi Sankyo Quarterly Reports.

Stockpile Market Opportunity

- Stockpile/government market
  - Pre-pandemic ~US$8bn built over 4-5 years
  - Governments' inventories stockpiled for an epidemic or pandemic
    - Large orders and specific buyers
  - Pandemics spread worldwide and infect a large proportion of the population
    - Occur irregularly: Approximately 3 each century for the last 300 years
    - Major outbreaks: 1918 Spanish Flu, 1957 Asian Flu, 1968 Hong Kong flu, 2009 Swine Flu
    - Can cause high mortality: Spanish Flu killed 50 million people
    - Typically occur when a new strain is transmitted to humans from another species
  - Distribution channel – direct sale business to government

- Key drivers of the stockpile market
  - Availability
  - Risk with Tamiflu resistance
  - Drug interactions and side effects with Tamiflu

Sources: HHS Pandemic Planning Update (March 2008);WHO website: Antiviral use and the risk of drug resistance (Sept 25, 2009); U.S. National Biodefense Science Board Public Meeting Minutes (Sept 25, 2009)

Global Stockpile Market

- ~$US2bn pa spent on major national stockpiles
- WHO recommends stockpile to cover 25%+ of the population
  - US has 35%+ policy
  - Many other countries aiming for 50%+ coverage

Global Stockpiles Measured In Courses of Treatment



- Relenza and Tamiflu have shelf lives of 5 and 7 years, respectively
  - National stockpiles began in 2004
  - A portion of the US stockpile of Tamiflu expires from FY2012
  - Rebalancing from 15:85 Relenza:Tamiflu towards 50:50

Relenza Royalties

- Royalty to Biota is 7% net
  - Paid 30 June, 12 months in arrears to 30 April
- Key markets patent expiry
  - US – Dec 2014
  - Europe – May 2015
  - Japan – Jul 2019
- GSK production capacity 2009
  - 90m Diskhaler, 100m Rotahaler*
- Relenza to participate in government stockpile replenishments
  - USA and UK recommendation is to increase to 50%
- Despite abatement of pandemic, influenza remains a continued threat

Relenza Royalties (F07-F10)



Fiscal Year ends 30 June

Laninamivir

Second Generation Influenza Antiviral

- Laninamivir octanoate is a pro-drug converted to laninamivir in the lung
- Marketed as Inavir ® (Daiichi Sankyo) in Japan (approved October 2010)
- Single 40mgm dose for treatment, “one and done”
  - Relenza 10mgm bd 5 days, Tamiflu 75mgm bd 5 days
- Once weekly for prevention
  - Relenza 10mgm daily, Tamiflu 15mgm daily
- Novel, disposable, IP protected inhaler
- Broad strain antiviral efficacy (4AH5N1,9AH1N1)
  - Effective against Tamiflu resistant clinical isolates
- Significant dosing advantage
  - Reduced stockpile/distribution
  - Enhanced compliance

Inavir ® Dry Powder Inhaler

Novel Patented, Easy to Use Disposable Inhaler

- Marketed in Japan by Daiichi Sankyo with royalties to Biota
  - Approximately 4-6% on sales
  - Production capacity guidance: 3m courses in Year 1, 10m Year 2
- Registration supported by strong clinical data in Japan
  - Phase II/III pediatric (treatment) trial completed in 2009
  - Phase III trial in adults (treatment) completed in 2009
  - Phase III prophylaxis trial to be completed
- Laninamivir is co-owned with Daiichi Sankyo
  - Daiichi Sankyo hold marketing rights in Japan
  - ROW marketing rights not yet assigned

BARDA Contract Overview with Biota

- US$231M contract for advanced development of laninamivir to lead to US NDA within 5 years
- Major components of contract are
  - Process development, scale-up, commissioning of US based manufacturing capability for laninamivir octanoate
  - Supply of clinical trial products
  - The completion of all relevant Phase I, Phase II and Phase III clinical studies for treatment
  - Preparation of NDA submission
- Cost reimbursement, plus 7% fee
- No dilution to shareholders

Solid Contract Progress to Date

- Drug substance manufacture protocols successfully transferred from Daiichi-Sankyo and reproduced at non-Japanese sites
  - Drug substance properties currently under assessment
- US-compliant polymers selected for device manufacture and prototype devices produced
  - Device performance consistent with Japanese devices
  - Device design optimisation completed
  - Moulding tool manufacture underway
- Clinical trials to support cardiac and respiratory safety commence in Q2 2012
- Clinical trial to study absorption, distribution, metabolism and excretion of laninamivir to commence Q4 2012
- Phase II efficacy study in adults due to commence Q2 2013 (southern hemisphere)

Contract Progress – Key Subcontractors

- Subcontracts are in place for
  - Drug substance manufacture
  - Drug product manufacture
  - Device manufacture
  - Clinical trials

PhosLyra

- PhosLyra is for end stage renal disease
- Product was sold to Fresenius USA Manufacturing Inc in 2006
- Potential royalty income on global sales
  - Double digit royalty >US$32M annual sales
- Royalty period runs to November 2016

Human Rhinovirus - BTA798 (vapendavir)

Treatment & Prophylaxis **MOA: capsid binder** **Oral delivery**

- Oral small molecule inhibitor of human rhinovirus (HRV)
  - Binds to capsid protein on surface of virus particle
  - Potent, broad spectrum HRV antiviral
    - EC50 < 100nM for ~ 90% of HRV serotypes
- Target markets
  - Serious complications in patients with asthma, COPD, Cystic Fibrosis
  - Patients with compromised immune systems (chemotherapy, transplants)
- Excellent safety package from non-clinical studies
- Phase IIa challenge study successfully demonstrated proof-of-concept in humans, reducing incidence and severity of HRV infection
- Phase IIb trial in patients with chronic asthma successfully met primary end point in March 2012
- Protected by comprehensive patent estate

A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled Study in Asthmatic Adults with Symptomatic, Naturally Acquired Human Rhinovirus Infection

rhino study

Phase IIb Trial Design and Endpoints

- Trial Design
  - Conducted over two consecutive seasons in 48 sites in the United States
  - Asthma patients were pre-screened for eligibility and then enrolled in the study if they developed a cold
  - Once enrolled, the patients received either 400 mg of BTA798 or placebo twice daily for six (6) days
  - 300 subjects were enrolled and 93 of these were confirmed infected with a human rhinovirus
- Trial Endpoints
  - The trial's primary efficacy endpoint used WURSS-21 (Wisconsin Upper Respiratory Symptom Survey-21) to assess the severity of cold symptoms for fourteen (14) days after the onset of illness*
  - Secondary endpoints included lung function, asthma control and virology
  - Safety was monitored throughout the study
- ***High WURSS scores have previously been shown to predict subsequent deterioration in asthma control***

The Primary Endpoint was Met

- When compared to placebo BTA798 treatment resulted in a statistically significant reduction in the severity score of cold symptoms over days 2 through 4 (p=0.028)



The Difference in Mean WURSS Scores on Days 4-14 was Statistically Significant



Other Secondary Endpoints

- Lung Function
  - Evening peak expiratory flow (PEF) was significantly higher (better) in the BTA798-treated group on day 5 (p=0.023)
  - This difference was clinically significant (LSMD of 29.4 L/min compared to a clinically significant threshold of 20.0 L/min)
- Asthma Control
  - Reduction in the use of asthma reliever medication (e.g. Ventolin ®) showed a positive trend toward improvement in the BTA798 group as early as day 3 of treatment
    - On day 13 BTA798 treated subjects used approximately half that of placebo recipients (1.22 puffs/day for the placebo group to 0.67 puffs/day for the BTA798 group, p=0.045)
- Virology
  - BTA798 treated subjects showed a statistically significant lower incidence of virus infection (74.4%) compared to placebo (91.4%) on day 3, as measured by PCR of nasal swabs (p=0.025)
- Safety
  - There were no serious adverse events and generally BTA798 was well tolerated

Next Steps

- Partnering discussions to recommence in near future
- Future development builds off this successful Proof-of-Concept
  - Dose optimisation
  - Clinical and non-clinical activities to support regulatory approvals

Financial Overview

Biota Revenue Detail

	FY Ended June 30,			HY Ended 31 Dec,
(In A$ Millions)	**2009**	**2010**	**2011**	**2011**
Royalties				
Relenza	45.0	63.7	6.6	0.7
Inavir	-	-	2.9	0.7
Revenue under BARDA contract	-	-	-	4.3
Collaboration Income	12.6	1.4	0.6	-
NIH Grant	2.8	3.8	2.5	0.2
Interest	2.9	2.5	4.4	1.8
Other	20.0	-	-	-
	83.3	**71.4**	**17.0**	**7.8**

- 2011 - Post swine flu Relenza royalties subdued
- Inavir - Launch occurred in Japan in Oct 2010

Biota Historical Income Statements

(In A$ Millions)	FY Ended June 30, 2009	2010	2011	HY Ended 31 Dec, 2011
Revenue	**83.3**	**71.4**	**17.0**	**7.8**
Expenses				
Research & development	13.3	21.7	20.7	8.1
Amortisation of antibacterial programs acquired	-	8.8	2.9	-
Product & clinical development	11.3	11.2	15.6	7.8
Business development	1.0	1.0	0.8	0.5
Sub royalty	4.3	4.1	1.2	0.6
Corporate	11.6	4.3	5.0	2.5
Total expense	41.5	51.2	46.2	19.4
PBT	**41.8**	**20.2**	**(29.2)**	**(11.6)**
Income tax credit/(expense)	(3.6)	(4.0)	1.1	0.6
PAT	**38.2**	**16.2**	**(28.1)**	**(11.0)**

2011 commentary

- Royalties: Relenza $6.6m, Inavir $2.9m
- Phase IIb HRV clinical spend $10.6m, GYR $5.1m
- Sub-royalty: amortization of CSIRO & VCP buyout

Biota Balance Sheets

(In A$ Millions)	June 30, 2011	December 31, 2011
Cash	70.0	56.5
Receivables	4.1	7.3
Plant & equipment	5.4	5.4
Intangible assets	3.0	2.4
Deferred tax assets	1.1	1.7
	83.6	73.3
Payables	4.1	4.4
Deferred revenue	0.1	0.5
Current tax liability	-	-
Provisions & performace payment	2.5	2.2
	6.7	7.1
Net assets/Net equity	**76.9**	**66.2**

- Strong cash balances held
- Intangible assets: principally CSIRO & VCP royalty buyout
- Deferred revenue: NIH funds received in advance

Opportunity Summary

- Following the closing of the merger, Biota Pharmaceuticals, Inc. will have
  - Three royalty generating products, Relenza, Inavir and potentially PhosLyra
  - Two clinical programs
    - Vapendavir (a phase III-ready human rhinovirus program)
    - Laninamivir (a long acting anti-influenza neuraminidase inhibitor) - US $231 million contract with BARDA for the advanced development,
  - NicVAX interest
  - Pre-clinical programs, including respiratory syncytial virus (RSV), hepatitis C (HCV-NN), broad spectrum antibiotic targeting gyrase (GYR)
  - Over US$100 million in cash with which to develop its program pipeline

Appendix

Preclinical Programs

Expected Upcoming Key Events

Biota Pharmaceuticals – Potential For A Series of Value-Creating Events



Respiratory Syncytial Virus

Respiratory Syncytial Virus (RSV)

Treatment **MOA: fusion inhibitor** **Oral delivery**

- Product advantages for unserved infant and elderly markets
  - U.S. mortality in the elderly estimated at 17,000 deaths per year
- Potential RSV market for treatment and prophylaxis >US$4bn
  - MedImmune (AZ) dominates prophylaxis market with Synagis ® >US$1bn
    - Synagis – mAb by injection and limited reimbursement scope
  - No treatment product available
- Solid progress with new lead candidate
  - RSV fusion inhibitor
- Strong IP position
  - Solely owned by Biota



RSV Fusion Inhibitor

- RSV antiviral compound ready to commence GLP non-clinical studies
- Completed preliminary oral bioavailability, PK, single dosing and repeat dosing pilot safety studies in animals (inc. up to 28d multidose studies in dogs and monkeys)
- Favourable PK profiles and safety margins demonstrated in animals
  - Cotton rat efficacy test showed significant reduction in viral load in cotton rats orally dosed with Biota compound prior to infection with RSV

qRT-PCR Analysis of RSV NS1 Lung mRNA Expression



*p<0.05 when compared to the NS1 level in mock-treated, infected animals sacrificed on the same day

Hepatitis C Non Nucleoside (HCV-NN)

- Non-nucleoside NS5b inhibitor
- Nanomolar pan-genotypic
- Intended for Interferon free combination
- Active in HCV replicon
- Orally bioavailable
- On track to nominate preclinical candidate Q2 2012
- Strong IP position
  - Solely owned by Biota

Gyrase (GYR) Anti-bacterial

- GyrB/ParE inhibitor
- Equivalent or superior to Zyvox ™ in multiple animal models
- IV/ Oral switch profile
- On track to nominate preclinical candidate Q2 2012
- Effective against multidrug resistant bacteria
- Unique resistance profile and very low resistance frequency
- Strong IP position
  - Solely owned by Biota

Further Information Regarding Biota

Peter Cook
CEO & Managing Director
+61 3 9915 3720
p.cook@biota.com.au

Damian Lismore
CFO
+61 3 9915 3721
d.lismore@biota.com.au

www.biota.com.au

Additional information on subcontractors appointed on BARDA contract

Subcontractors

- Aptuit
  - A pharmaceutical services company that delivers early to mid-phase drug development solutions including API manufacture
- Albany Molecular Research, Inc. (AMRI)
  - A global contract research organization providing manufacture of API and drug products for existing and experimental new drugs
  - Located in the United States, Europe, and Asia
- INC Research
  - A leading global CRO providing the full range of Phase I to IV clinical development
  - Broad therapeutic expertise and commitment to operational excellence

Subcontractors

- Nypro
  - Global plastics leader serving the Healthcare, Packaging and Consumer and Electronics industries
  - 41 locations in 14 countries
- Catalent
  - A leading provider of inhalation product development, manufacturing, and packaging offering comprehensive inhalation development services
    - Dosage form selection and technology assessment
    - Formulation development and analytical testing
    - Supply of toxicological and clinical trial materials
    - Commercial-scale manufacturing
    - Packaging services